Healthcare News
GLP-1 and health: Beyond weight loss in the Ozempic era
This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people with diabetes and obesity.
Once-weekly eloralintide leads to 20% weight loss in Phase II trial
A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight loss up to 20% over 48 weeks in adults with obesity or overweight without type 2 diabetes.
Popular weight-loss drugs show added heart protection for diabetes patients
Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this result using insurance claims data.
Weight-loss surgery bests medical weight management for obesity-related risk mitigation
Bariatric surgery is associated with a significantly lower risk for developing major metabolic comorbidities compared with a medical weight management program for adults with obesity, according to a study published online Sept. 9 in JAMA Network Open.
Human-AI coaching models boost weight loss
Adding human coaches to artificial intelligence-powered weight-loss programs significantly boosts user success, underscoring the value of hybrid human-AI models in digital health, a new study suggests.